Speaking at a recent Technology Networks’ symposium, Dr. Jason Reeves explained how AI is changing the development of ...

A study by the Neuropsychopharmacology and IBeA groups of the University of the Basque Country (UPV/EHU) paves the way to ...

The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic ...

Artificial intelligence can help. The stories below highlight startup companies that use AI to spot patterns that humans ...

The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...

The Cell-Based Assays Market is projected to grow from $35.3 billion in 2024 to $56.3 billion by 2029, at a 9.8% CAGR, driven by demand for drug discovery, ADME/toxicity testing, and precision ...

The Organ-on-a-Chip (OOAC) technology simulates various organ systems depending on the specific cell types seeded onto the ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

Angle announced on Friday the successful completion of assay development projects for AstraZeneca and Eisai, further ...

In recent years neuroimaging biomarkers, such as positron emission tomography (PET) ligands, have significantly contributed to the clinical stages of CNS drug development by assisting in dose ...

Valo Health, Inc. ("Valo"), a biotechnology company focused on transforming the drug discovery and development process using ...